Crawford J, Dale DC, Lyman GH. Chemotherapy‐induced neutropenia: risks, consequences, and new directions for its management. <i>Cancer</i>. (2004) 100(2):228–37.

Crawford, Jennifer L.; Dale, DC; Lyman, GH

doi:10.1002/cncr.20218

Cited by 312 publications

(457 citation statements)

References 0 publications

Supporting

Mentioning

417

Contrasting

Unclassified

Order By: Relevance

“…Neutropenia (a condition characterized by an abnormally low number of neutrophils) is the most serious form of hematologic toxicity associated with cancer chemotherapy, often limiting the doses of chemopharmaceuticals that a patient can tolerate (Crawford et al, 2004).…”

Section: Predictive Factors For Neutropenia After Docetaxel-based Sysmentioning

confidence: 99%

“…Chemotherapy-induced neutropenia is the most common and often dose limiting toxicity of cytotoxic anticancer treatment (Crawford et al, 2004). In the urologic field, the incidences of docetaxel-induced neutropenia in patients with Castration-Resistant Prostate Cancer (CRPC) is about 25% in western (Italiano et al, 2009) and 17% in Korean study (Lee et al, 2010), respectively.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Predictive Factors for Neutropenia after Docetaxel-Based Systemic Chemotherapy in Korean Patients with Castration-Resistant Prostate Cancer

Kwon¹,

Oh²,

Lee³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

The aim of this study was to determine predictive factors for neutropenia after docetaxel-based systemic chemotherapy in patients with castration-resistant prostate cancer (CRPC). The study included 40 Korean CRPC patients who were treated with several cycles of docetaxel plus prednisolone from May 2005 to May 2012. Patients were evaluated for neutropenia risk factors and for the incidence of neutropenia. In this study, nine out of forty patients (22.5%) developed neutropenia during the first cycle of docetaxel-based systemic chemotherapy. Four experienced grade 2, three grade 3, and one grade 4 neutropenia. Multivariate analysis showed that pretreatment white blood cell (WBC) count (p=0.042), pretreatment neutrophil count (p=0.015), pretreatment serum creatinine level (p=0.027), and pretreatment serum albumin level (p=0.017) were significant predictive factors for neutropenia. In conclusion, pretreatment WBC counts, neutrophil counts, serum creatinine levels, and serum albumin levels proved to be significant independent risk factors for the development of neutropenia induced by docetaxel-based systemic chemotherapy in patients with CRPC.

show abstract

Section: Predictive Factors For Neutropenia After Docetaxel-based Sysmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Predictive Factors for Neutropenia after Docetaxel-Based Systemic Chemotherapy in Korean Patients with Castration-Resistant Prostate Cancer

Kwon¹,

Oh²,

Lee³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

show abstract

“…In general, it is considered that the higher the dose intensity, the greater the chance that the optimal dose is approached (Frei and Canellos, 1980). Neutropenia is one of the most important dose-limiting toxicities of cytotoxic drugs, often necessitating a reduction from the initial dosage (Crawford et al, 2004). Therefore, many oncologists may consider that the absence of haematological toxicity will raise the hope of an adequate tumour response without myelosuppression.…”

mentioning

confidence: 99%

Predictive value of chemotherapy-induced neutropenia for the efficacy of oral fluoropyrimidine S-1 in advanced gastric carcinoma

et al. 2007

View full text Add to dashboard Cite

Myelosuppression that occurs during chemotherapy has been reported to be a predictor of better survival in patients with breast or lung carcinomas. We evaluated the prognostic implications of chemotherapy-induced neutropenia in advanced gastric carcinoma. Data from a prospective survey of oral fluoropyrimidine S-1 for advanced gastric cancer patients in Japan were reviewed. We identified 1055 untreated patients with adequate baseline bone marrow function. During treatment with S-1, a total of 293 (28%) patients experienced grade 1 or higher neutropenia. The adjusted hazard ratio of death for the presence of neutropenia, as compared with the absence of such toxicity, from a multivariate Cox model was 0.72 (95% confidence interval, 0.54 -0.95; P ¼ 0.0189) for grade 1 neutropenia, 0.63 (0.50 -0.78; Po0.0001) for grade 2 neutropenia and 0.71 (0.51 -0.98; P ¼ 0.0388) for grade 3 -4 neutropenia. These findings suggest that the occurrence of neutropenia during chemotherapy is an independent predictor of increased survival in patients with advanced gastric cancer, whereas the absence of such toxicity indicates that the dosages of drugs are not pharmacologically adequate. Monitoring of neutropenia in patients who receive chemotherapy may contribute to improved drug efficacy and favourable survival.

show abstract

“…Leucopenia, chemotherapy-induced myelotoxicity, is one of the major toxic effects of chemotherapy (Crawford et al, 2004). In our study, CTX alone induced leucopenia of H22 tumor-bearing mice, however, when the middle or high dose of Se-B.…”

Section: Effect Of Se-b Longum On Immune Function Of Tumorbearing Micementioning

confidence: 45%

Preparation of Selenium-enriched Bifidobacterium Longum and its Effect on Tumor Growth and Immune Function of Tumor-Bearing Mice

Wang¹,

Wang²,

Wang³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

In this study, we demonstrated selenium (Se) accumulation in Bifidobacterium longum strain (B. longum) and evaluated the effect of Se-enriched B. longum (Se-B. longum) on tumor growth and immune function in tumor-bearing mice. Analysis using high-performance liquid chromatography-inductively coupled plasma mass spectrometry (HPLC-ICP-MS) revealed that more than 99% of Se in Se-B. longum was organic, the main component of which was selenomethionine (SeMet). In the in vivo experiments, tumor-bearing mice (n=8) were orally administrated with different doses of Se-B. longum alone or combined with cyclophosphamide (CTX). The results showed that the middle and high dose of Se-B. longum significantly inhibited tumor growth. When Se-B. longum and CTX were combined, the antitumor effect was significantly enhanced and the survival time of tumor-bearing mice (n=12) was prolonged. Furthermore, compared with CTX alone, the combination of Se-B. longum and CTX stimulated the activity of natural killer (NK) cells and T lymphocytes, increasing the levels of interleukin-2 (IL-2) and tumor necrosis factor-α (TNF-α), and the leukocyte count of H22 tumor-bearing mice (n=12).

show abstract

Crawford J, Dale DC, Lyman GH. Chemotherapy‐induced neutropenia: risks, consequences, and new directions for its management. Cancer. (2004) 100(2):228–37.

Abstract: The original article to which this Erratum refers was published in

Cited by 312 publications

References 0 publications

Predictive Factors for Neutropenia after Docetaxel-Based Systemic Chemotherapy in Korean Patients with Castration-Resistant Prostate Cancer

Predictive Factors for Neutropenia after Docetaxel-Based Systemic Chemotherapy in Korean Patients with Castration-Resistant Prostate Cancer

Predictive value of chemotherapy-induced neutropenia for the efficacy of oral fluoropyrimidine S-1 in advanced gastric carcinoma

Preparation of Selenium-enriched Bifidobacterium Longum and its Effect on Tumor Growth and Immune Function of Tumor-Bearing Mice

Contact Info

Product

Resources

About